Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lyell Immunopharma ( (LYEL) ) just unveiled an update.
On October 31, 2025, Lyell Immunopharma announced key leadership changes, appointing Lynn Seely, M.D. as interim principal financial officer and Veronica Sanchez Bulis as principal accounting officer. These appointments are part of the company’s strategic efforts to strengthen its financial leadership and ensure robust financial operations, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (LYEL) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
Lyell Immunopharma’s overall score is primarily impacted by its financial challenges, with zero revenue and persistent losses posing significant risks. Technical analysis provides some optimism with positive momentum indicators. However, valuation concerns due to negative earnings weigh heavily on the score.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies to treat cancer. The company is dedicated to advancing cell-based therapies to enhance the body’s immune response against tumors.
Average Trading Volume: 40,597
Technical Sentiment Signal: Hold
Current Market Cap: $320.1M
For an in-depth examination of LYEL stock, go to TipRanks’ Overview page.